Current Report · Items 8.01, 9.01 · 8-K
ProPhase Labs, Inc.
Other Events
Item 8.01 Other Events The Securities and Exchange Commission requires disclosure of material changes and events that the registrant deems of importance to security holders via Form 8-K filings. On February 3, 2026, ProPhase Labs, Inc.…
Filed Feb 13, 2026Accepted Feb 13, 2026, 12:15 PM ESTCIK 868278Accession 0001493152-26-006784
Company context
We are a next-generation biotech, genomics and consumer products company. We are also focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds, and diagnostics.
Current securities
Historical securities (2)
Registered securities in this filing
PROPHASE LABS, INC. · 8-K · Filed 2026-02-13
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, par value $0.0005
- Symbol
- PRPH
- Exchange
- Not supplied
- Classification
- COMMON
Filing context
Context: AsOf2026-02-03
Dimensions: Not supplied
Accession 000149315226006784 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events
The
Securities and Exchange Commission requires disclosure of material changes and events that the registrant deems of importance to security
holders via Form 8-K filings. On February 3, 2026, ProPhase Labs, Inc. (“The Company”) issued a press release announcing
that it has initiated a potential sale or strategic partnership process for BE-Smart™, its clinically validated esophageal cancer
risk stratification test. BE-Smart™ is a CLIA-certified, CAP-accredited laboratory-developed test (LDT) that is ready for commercialization
under the LDT regulatory framework. The Company has initiated target outreach to more than seventy (70) potential acquirers.
The
press release also provided a positive update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19
testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings. Based on recent analysis, the Company now
believes that more than sixty percent (60%) of aggregate claims consist of commercial payors that partially reimbursed claims. This is
generally associated with higher recovery rates and more favorable settlement dynamics.
A
copy of the press release is furnished as Exhibit 1.1 to this Current Report on Form 8-K.